英文药名：Kenicef intravenous(Cefodizime Sodium) 中文药名：头孢地秦钠注射剂 生产厂家：大鹏药品 ケニセフ静注用1g 治疗类别名称 头孢类抗生素制剂 商標名 Kenicef intravenous 1g 構造式 一般名 セフォジジムナトリウム（Cefodizime Sodium） 略号 CDZM 化学名 Disodium (6R,7R)-7-[(Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetylamino]-3-[(5-carboxylatomethyl-4-methylthiazol-2-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate 分子式 C20H18N6Na2O7S4 分子量 628.63 融点 約217℃（分解） 分配係数 0.001以下（pH7、オクタノール／水系溶媒） 性状 它是白色结晶粉末，以淡黄白色。非常易溶于水，并在乙腈或乙醇（99.5）几乎不溶。 药效药理 1. 抗菌作用 (1) 体外抗菌活性 在革兰氏阳性和革兰氏阴性有氧和厌氧菌广泛的抗菌谱。特别是，与链球菌属，革兰氏阳性菌和淋病奈瑟氏球菌，如肺炎链球菌，大肠杆菌，克雷伯氏菌，变形杆菌，普罗维登斯菌属，对革兰氏阴性菌如流感嗜血杆菌的强抗菌活性。此外，莫拉（布兰汉）卡他莫拉菌，革兰氏阴性菌和消化链球菌等摩Morugani，类杆菌，抗菌力也为厌氧菌普雷沃观察（除普雷沃Bibia）。 (2) 体内抗菌活性 在正常和感染防御不容忍小鼠的实验性感染模型中，已经获得比从最小抑制浓度预测优良的治疗效果。 2. 感染的保护因素合作杀菌作用 在体外正常和感染防御不容忍小鼠的该代理多形核白细胞治疗细菌，是公吞噬灭菌的吞噬细胞如巨噬细胞，在补体也已经观察合作杀菌作用。另外，在小鼠腹膜内接种，已经证实，细菌的生长被抑制。 3. 作用机理 由细菌的细胞壁合成抑制，青霉素结合蛋白（的PBPs）的抗微生物活性具有高度亲和力，作用杀菌。此外，稳定的β-内酰胺酶。 适应症 属于，肺炎链球菌，淋球菌，莫拉链球菌的头孢地嗪感性（布兰汉）卡他莫拉菌，大肠杆菌，柠檬酸杆菌属，克雷伯氏菌属，肠杆菌属，沙雷氏菌属，变形杆菌属，摩根氏Morugani，普罗维登斯菌属，流感嗜血杆菌，肽链球菌，类杆菌，普氏菌（除普雷沃Bibia） 败血症，咽，喉炎，扁桃体炎（扁桃体的炎症，包括扁桃体周围脓肿），急性支气管炎，肺炎，肺脓肿，慢性呼吸系统疾病的继发感染，膀胱炎，肾盂肾炎，尿道炎，腹膜炎，腹腔内脓肿，胆囊炎，胆管炎，肝脓肿，前庭大腺炎症，宫腔感染，子宫附件炎，子宫壁结缔组织炎，化脓性脑膜炎，中耳炎，鼻窦炎 用法用量 成人，为1天1-2克（效价）两次静脉注射或静脉滴注。 通常，儿童静脉注射或静脉滴注分为601天-80毫克（效价）/kg的三到四倍。 此外，年龄，将适当地增加或根据状况下降，4G1天的成人是难治性或严重感染（效价），一天为120mg（效价）的儿童/公斤，直到增加量，除以给药。 在静脉内注射溶解于注射用水，生理盐水或葡萄糖注射液，缓慢地注入。另外，在静脉内输注的时间被注射溶解在补液。 包装规格 1克：10瓶 制造厂商 大鹏药业有限公司 完整处方资料附件：http://di-pedia.com:808/DIC_GOOCO/Attach/6132423F2057_1_03.html Kenycef for intravenous injection 1g(Cefodizime Sodium) Name of drug classification Cephem antibiotic preparation Sales name Kenycef for intravenous injection 1g Common name Cefodizime Sodium Abbreviation CDZM Chemical name 3-[(5-carboxylatomethyl-4-methylthiazol-2-yl) -2,3-dihydroxybenzaldehyde was used instead of Disodium (6R, 7R)-7-[ Sulfanylmethyl] -8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylate Molecular formula C20H18N6Na2O7S4 Molecular weight 628.63 Melting point About 217 ° C (decomposition) Distribution coefficient 0.001 or less (pH 7, octanol/aqueous solvent) Property It is a white to pale yellow white crystalline powder. It is very soluble in water and hardly soluble in acetonitrile or ethanol (99.5). composition Component · Content Cefodizime sodium 1.0 g (potency) in one bottle Contraindications Patients with a history of shock due to ingredients of this drug Indication or effect Adaptive fungal species Cefodizime is susceptible to Streptococcus sp., Streptococcus pneumoniae, Neisseria gonorrhoeae, Moraxella (Branhamellara), Catharillis, Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus, Morganella · Morganii, Providencia, Haemophilus influenzae Streptococcus, Bacteroides, Prevotella (except Prevotella vivia) Indication Secondary infection with septicemia, pharyngo/laryngitis, tonsillitis (including amygdala, amygdal abscess), acute bronchitis, pneumonia, lung abscess, secondary infection of chronic respiratory lesions, cystitis, pyelonephritis, urethritis, peritonitis, Intraabdominal abscess, cholecystitis, cholangitis, hepatic abscess, Bartholinitis, intrauterine infection, uterine adnexitis, uterine fibrosis, suppurative meningitis, otitis media, sinusitis Usually, for adults, cefodizime sodium is administered intravenously or intravenously by intravenous injection or intravenous drip by dividing 1 to 2g (potency) per day into two doses. Usually, children are given intravenous injection or intravenous infusion intravenously 60 to 80 mg (potency)/kg a day divided into 3 to 4 times. Incidentally, depending on age and symptoms, it will be increased or decreased accordingly. However, for refractory or severe infections, increase by 4g/day (titer) in adults to 120 mg (potency)/kg/day in children, dividedly administered. For intravenous injection, dissolve in water for injection, physiological saline or glucose injection and inject slowly. Also, at the time of intravenous infusion, dissolve in the replacement fluid and inject it. When using this drug, in order to prevent the development of resistant bacteria, as a rule to confirm susceptibility, only for the minimum period necessary for treatment of the disease. Careful Administration Patients with a history of hypersensitivity to penicillin antibiotics A patient having a constitution that is likely to cause an allergic symptom such as bronchial asthma, rash, urticaria or the like by himself, parents or brothers Patient with advanced renal impairment [As the blood concentration is sustained, dosing should be administered at dosage intervals or at dosing intervals. ] Patients with hepatic impairment [Incidence of side effects of the liver increases] Patients with poor oral intake or patients with parenteral nutrition, patients with poor general condition [Vitamin K deficiency symptoms may occur, so observe thoroughly] Elderly (see "Administration to the elderly" section) Serious side effects Expression frequency is described in [(). Unspecified frequency unknown] shock As it may cause shock, observe thoroughly, if symptoms appear, discontinue administration and take appropriate measures. Anaphylactoid symptoms Since anaphylactoid symptoms (redness, dyspnea, edema, convulsions, etc.) (less than 0.1%) may occur, observe thoroughly, if symptoms appear, discontinue administration and take appropriate measures . Acute renal failure Acute renal failure (less than 0.1%) may occur, so conduct observation thoroughly by periodically conducting an examination and if appropriate, take appropriate measures such as discontinue administration. Pseudomembranous colitis Serious colitis accompanied by bloody stools such as pseudomembranous colitis (less than 0.1%) may occur. If abdominal pain, frequent diarrhea appears, take appropriate measures such as immediately discontinue administration. Agranulocytosis, thrombocytopenia Since agranulocytosis and thrombocytopenia (less than 0.1%) may occur, observe thoroughly by conducting an examination regularly and if abnormality is found, take appropriate measures such as discontinue administration about. Toxic epidermal necrosis (Lyell syndrome), skin mucosa ocular syndrome (Stevens-Johnson syndrome) Toxic epidermal necrolysis, skin mucosal ocular syndrome may appear, so when such symptoms appear, administration should be stopped and appropriate measures should be taken. Medicinal pharmacology Antibacterial action In vitro antibacterial activity It shows a broad antimicrobial spectrum for gram positive and negative aerobic bacteria and anaerobic bacteria. In particular, it has strong antibacterial activity against Gram-positive bacteria such as Streptococcus, Streptococcus pneumoniae and Gram-negative bacteria such as Neisseria gonorrhoeae, Escherichia coli, Klebsiella, Proteus, Providencia, Haemophilus influenzae. In addition, antibacterial activity has also been recognized for gram negative bacteria such as Moraxella (Branhamella) · catarrhalis, Morganella · Morganii and the like, and anaerobic bacteria of Peptostreptococcus, Bacteroides, Prevotera (except Prevotelera vivia) . In vivo antibacterial activity Excellent therapeutic effects are obtained in experimental infectious disease models in normal and infectious defense-reducing mice than expected from the minimum growth inhibitory concentration. Cooperation with infection protective factors Bactericidal action Bacteria treated with this drug are normally phagocytized and sterilized by phagocytes such as polymorphonuclear leukocytes and macrophages of mice which are normal in normal condition and reduced in infection protective ability, and cooperative bactericidal action with complement has been recognized. Furthermore, it has been confirmed that bacterial growth is suppressed in mouse intraperitoneal inoculation. Mechanism of action It exhibits antibacterial action by bacterial cell wall synthesis inhibition, has high affinity for penicillin-binding proteins (PBPs), and acts bactericidally. It is also stable against β-lactamase.